Investigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010 Final Report of National Narcolepsy Study Steering Committee

Hdl Handle:
http://hdl.handle.net/10147/219671
Title:
Investigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010 Final Report of National Narcolepsy Study Steering Committee
Authors:
Department of Health (DoH)
Issue Date:
20-Apr-2012
URI:
http://hdl.handle.net/10147/219671
Additional Links:
http://www.dohc.ie
Item Type:
Report
Language:
en
Description:
In August 2010 the Swedish pharmacovigilance authority reported that it was investigating six cases of narcolepsy reported by health care professionals as a possible adverse event following the use of Pandemrix vaccine, used during the H1N1 2009 pandemic. This was followed shortly by reports from the Finnish National Institute for Health and Welfare (THL) noting there had been a more than expected number of cases of narcolepsy in children and adolescents that year. On 23rd September, the Committee on Human Medicinal Products (CHMP) of the EMA concluded in its initial review of available data that the available evidence did not confirm a link but that more research was needed.
Keywords:
INFLUENZA; VACCINES
Local subject classification:
NARCOLEPSY
Sponsors:
In August 2010 the Swedish pharmacovigilance authority reported that it was investigating six cases of narcolepsy reported by health care professionals as a possible adverse event following the use of Pandemrix vaccine, used during the H1N1 2009 pandemic. This was followed shortly by reports from the Finnish National Institute for Health and Welfare (THL) noting there had been a more than expected number of cases of narcolepsy in children and adolescents that year. On 23rd September, the Committee on Human Medicinal Products (CHMP) of the EMA concluded in its initial review of available data that the available evidence did not confirm a link but that more research was needed.

Full metadata record

DC FieldValue Language
dc.contributor.authorDepartment of Health (DoH)en_GB
dc.date.accessioned2012-04-20T15:11:51Z-
dc.date.available2012-04-20T15:11:51Z-
dc.date.issued2012-04-20-
dc.identifier.urihttp://hdl.handle.net/10147/219671-
dc.descriptionIn August 2010 the Swedish pharmacovigilance authority reported that it was investigating six cases of narcolepsy reported by health care professionals as a possible adverse event following the use of Pandemrix vaccine, used during the H1N1 2009 pandemic. This was followed shortly by reports from the Finnish National Institute for Health and Welfare (THL) noting there had been a more than expected number of cases of narcolepsy in children and adolescents that year. On 23rd September, the Committee on Human Medicinal Products (CHMP) of the EMA concluded in its initial review of available data that the available evidence did not confirm a link but that more research was needed.en_GB
dc.description.sponsorshipIn August 2010 the Swedish pharmacovigilance authority reported that it was investigating six cases of narcolepsy reported by health care professionals as a possible adverse event following the use of Pandemrix vaccine, used during the H1N1 2009 pandemic. This was followed shortly by reports from the Finnish National Institute for Health and Welfare (THL) noting there had been a more than expected number of cases of narcolepsy in children and adolescents that year. On 23rd September, the Committee on Human Medicinal Products (CHMP) of the EMA concluded in its initial review of available data that the available evidence did not confirm a link but that more research was needed.en_GB
dc.language.isoenen
dc.relation.urlhttp://www.dohc.ieen_GB
dc.subjectINFLUENZAen_GB
dc.subjectVACCINESen_GB
dc.subject.otherNARCOLEPSYen_GB
dc.titleInvestigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010 Final Report of National Narcolepsy Study Steering Committeeen_GB
dc.typeReporten
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.